1231414

TAGI Pharma, Inc. — FEI 3010167068

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 12, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
South Beloit, IL (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
891221 CFR 314.81(b)(2)Timely submission